Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Giachini, Fernanda R ^a   Leite, Romulo ^b   Osmond, David A ^c   Lima, Victor V ^a   Inscho, Edward W ^c   Webb, R Clinton ^c   Tostes, Rita C ^d  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLTHIOADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE; ANGIOTENSIN II; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; METHYLTHIO-ADP; NUCLEOTIDE; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; AORTA; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; VASOCONSTRICTION; VASODILATATION;

ADENOSINE DIPHOSPHATE; ANIMALS; AORTA; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HYPERTENSION; MALE; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RECEPTORS, PURINERGIC P2Y; THIONUCLEOTIDES; TICLOPIDINE; VASCULAR REMODELING; VASOCONSTRICTION; VASODILATION;

EID: 84898640565     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091890     Document Type: Article

References (46)

1. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, et al. (2004) ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood ve (Pubitemid 39350296)
2. Hellem AJ (1967) The role of platelet metabolism in adenosine diphosphateinduced platelet adhesiveness. Thromb Diath Haemorrh Suppl 26:193-196.
3. Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA (1961) Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192:531-532.
4. Baurand A, Raboisson P, Freund M, Leon C, Cazenave JP, et al. (2001) Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 412:213-221. (Pubitemid 32144936)
5. Wallentin L (2009) P2Y (12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30:1964-1977.
6. Dol-Gleizes F, Mares AM, Savi P, Herbert JM (1999) Relaxant effect of 2-methyl-thio-adenosine diphosphate on rat thoracic aorta: effect of clopidogrel. Eur J Pharmacol 367:247-253. (Pubitemid 29106377)
7. Steinhubl SR, Berger PB, Mann JT, Fry ET, De Lago A, et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420. (Pubitemid 35340537)
8. Gent M, Beaumont D, Blanchard J, Bousser MG, Coffman J, et al. (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329-1339. (Pubitemid 26383772)
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, et al. (2006) Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55:780-784. (Pubitemid 43343236)
10. Arazi HC, Badimon JJ (2012) Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis. Curr Pharm Des.
11. Graff J, Klinkhardt U, Westrup D, Kirchmaier CM, Breddin HK, et al. (2003) Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans. Br J Clin Pharmacol 56:321-326. (Pubitemid 37059660)
12. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, et al. (2003) Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther Mar; 73:232-241. (Pubitemid 36269674)
13. Storey RF, Wilcox RG, Heptinstall S (2002) Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 13:407-413. (Pubitemid 35346941)
14. Warnholtz A, Ostad MA, Heitzer T, Thuneke F, Frohlich M, et al. (2007) AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease. Atherosclerosis 194:439-445. (Pubitemid 47513075)
15. Giachini FR, Osmond DA, Zhang S, Carneiro FS, Lima VV, et al. (2009) Clopidogrel, independent of vascular P2Y12 receptor, improves the arterial function in small mesenteric arteries from Ang II-hypertensive rats. Clin Sci (Lond).
16. Lip GY, Felmeden DC, Dwivedi G (2011) Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev: CD003186.
17. Graciano ML, Nishiyama A, Jackson K, Seth DM, Ortiz RM, et al. (2008) Purinoceptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am J Physiol Renal Physiol 294:F161-169.
18. Safar ME, London GM, Asmar R, Frohlich ED (1998) Recent advances on large arteries in hypertension. Hypertension 32:156-161. (Pubitemid 28324141)
19. Rayment SJ, Ralevic V, Barrett DA, Cordell R, Alexander SP (2007) A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release. FASEB J 21:577-585. (Pubitemid 46213504)
20. Baurand A, Raboisson P, Freund M, Leon C, Cazenave JP, et al. (2001) Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 412:213-221. (Pubitemid 32144936)
21. Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK (1998) Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3', 5'-bisphosphate. Br J Pharmacol 124:1-3. (Pubitemid 28210035)
22. Von Kugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415-432.
23. Kim YC, Lee JS, Sak K, Marteau F, Mamedova L, et al. (2005) Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol 70:266-274. (Pubitemid 40823051)
24. Simon J, Filippov AK, Goransson S, Wong YH, Frelin C, et al. (2002) Characterization and channel coupling of the P2Y (12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 277:31390-31400. (Pubitemid 34968938)
25. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, et al. (2004) ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24:1810-1815. (Pubitemid 39350296)
26. Bender SB, Berwick ZC, Laughlin MH, Tune JD (2011) Functional contribution of P2Y1 receptors to the control of coronary blood flow. J Appl Physiol (1985) 111:1744-1750.
27. Saiag B, Hillaire-Buys D, Chapal J, Petit P, Pape D, et al. (1996) Study of the mechanisms involved in adenosine-5'-O-(2-thiodiphosphate) induced relaxation of rat thoracic aorta and pancreatic vascular bed. Br J Pharmacol 118:804-810.
28. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492. (Pubitemid 28477681)
29. Mitchell C, Syed NI, Tengah A, Gurney AM, Kennedy C (2012) Identification of contractile P2Y1, P2Y6, and P2Y12 receptors in rat intrapulmonary artery using selective ligands. J Pharmacol Exp Ther 343:755-762.
30. Shechter M, Shechter A, Hod H, Fefer P, Shenkman B, et al. (2012) Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction. Platelets 23:202-210.
31. Gkaliagkousi E, Passacquale G, Douma S, Zamboulis C, Ferro A (2010) Platelet activation in essential hypertension: implications for antiplatelet treatment. Am J Hypertens 23:229-236.
32. Umemura K, Kawai H, Ishihara H, Nakashima M (1995) Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn J Pharmacol 67:253-258.
33. Yao SK, McNatt J, Cui K, Anderson HV, Maffrand JP, et al. (1993) Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation 88:2888-2893. (Pubitemid 23360216)
34. Schafer A, Fraccarollo D, Pfortsch S, Loch E, Neuser J, et al. (2011) Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Basic Res Cardiol 106:485-494.
35. Zeng C (2010) Clopidogrel application: beyond coronary artery disease. Clin Sci (Lond) 118:459-461.
36. Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, et al. (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. J Thromb Thrombolysis 32:64-71.
37. Leach CM, Thorburn GD (1982) A comparative study of collagen induced thromboxane release from platelets of different species: implications for human atherosclerosis models. Prostaglandins 24:47-59. (Pubitemid 13228669)
38. Bautista LE (2003) Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 17:223-230. (Pubitemid 36592013)
39. Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, et al. (2012) Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond) 122:535-543.
40. Kaul S, Waack BJ, Padgett RC, Brooks RM, Heistad DD (1993) Altered vascular responses to platelets from hypercholesterolemic humans. Circ Res 72:737-743. (Pubitemid 23077764)
41. Virdis A, Duranti E, Taddei S (2011) Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin II. Int J Hypertens 2011:916310.
42. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM (2011) Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 13:e11.
43. Brown NJ, Vaughan DE (1996) The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease. Trends Cardiovasc Med 6:239-243. (Pubitemid 26376701)
44. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF (2007) Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12:113-122. (Pubitemid 46995474)
45. Palatini P, Casiglia E, Gasowski J, Gluszek J, Jankowski P, et al. (2011) Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health Risk Manag 7:725-739.
46. Touyz RM (2005) Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 90:449-455. (Pubitemid 40980144)